In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .
Simulated Driving Changes in Young Adults With ADHD Receiving Mixed Amphetamine Salts Extended Release and Atomoxetine
Background : Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder ( ADHD ) . Method : This was a r and omized , double-blind , placebo-controlled , crossover study of simulated driving performance with mixed amphetamine salts — extended release ( MAS XR ) 50 mg/day ( Cohort 1 ) and atomoxetine 80 mg/day ( Cohort 2 ) in young adults with ADHD . Results : Adults aged 19 to 25 years with AD/HD ( N = 19 ) who were administered MAS XR significantly improved overall simulated driving performance  versus placebo up to 12 hours after dosing . In contrast , there were no statistically significant differences in simulated-driving-performance scores  between atomoxetine and placebo . At endpoint , MAS XR reduced ADHD Rating Scale scores ≥ 30 % in 80 % of subjects , whereas atomoxetine achieved this level of improvement for 40 % . Limitations : Small sample size and use of simulated driving may limit generalizability of the findings . Conclusion : MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms . ( J. of Att . Dis . 2009 ; 12(4 ) 316 - 329
In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .